Aim: To evaluate the long-term efficacy and safety of ertugliflozin in adults with type 2 diabetes mellitus inadequately controlled on metformin. 
| INTRODUCTION
Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control in patients with type 2 diabetes mellitus (T2DM) via inhibition of renal glucose reabsorption and reduction of the renal threshold for glucose excretion. [1] [2] [3] Ertugliflozin is a selective SGLT2 inhibitor 4, 5 approved by the US Food and Drug Administration 6 and the European Medicines Agency 7 for the treatment of adults with T2DM. Across the Phase III VERTIS (eValuation of ERTugliflozin effIcacy and Safety) programme, ertugliflozin showed clinically meaningful reductions from baseline in HbA1c, fasting plasma glucose (FPG), body weight and blood pressure. [8] [9] [10] [11] [12] [13] The Phase III, randomized, double-blind VERTIS MET trial (ClinicalTrials.gov: NCT02033889) evaluated ertugliflozin versus placebo in adults with inadequately controlled T2DM receiving metformin monotherapy. The study population was enriched with postmenopausal women to enhance the ability to assess potential effects of ertugliflozin on bone mineral density (BMD). The study consisted of a 26-week placebo-controlled period (Phase A) followed by a 78-week extension (Phase B). At week 26, the primary time point, ertugliflozin was associated with significantly larger reductions from baseline in HbA1c, FPG, blood pressure and body weight than placebo. 10 Additionally, a larger proportion of participants with ertugliflozin had HbA1c <7.0% (53 mmol/mol) than placebo. Ertugliflozin was well tolerated, although an increased incidence of genital mycotic infections (GMIs) was observed. There was no adverse impact on BMD with ertugliflozin treatment at week 26. 10 Here, we report efficacy results at weeks 52 and 104 (Phase B) and safety results for the overall study (Phases A and B).
| MATERIALS AND METHODS
This study was conducted in compliance with the ethical principles Ethics Committee at each of the investigational centres, and written informed consent was obtained from all study participants. This study was conducted in 14 countries at 103 study centres.
All efficacy hypotheses were tested at week 26 and have been previously published, as have detailed descriptions of the eligibility criteria (Supplementary Methods, see the supporting information), and efficacy and safety assessments. 10 
| Study design and treatment
The design of the trial is shown in Supporting Information Figure S1 ; full details have been published previously. 10 The study consisted of 2 phases: a double-blind, placebo-controlled, 26-week treatment period (Phase A), and a double-blind, 78-week treatment extension period (Phase B). In Phase B, participants with fasting fingerstick glucose ≥6.1 mmol/L (≥110 mg/dL) and not rescued during Phase A received blinded glimepiride (for participants randomized to placebo) or glimepiride placebo (for participants randomized to ertugliflozin). In
Phase B, glycaemic rescue therapy with basal insulin was initiated in participants with FPG >11.1 mmol/L (>200 mg/dL) or HbA1c >8.0%
(64 mmol/mol) on maximum tolerated doses of glimepiride. Bone rescue therapy with any bone-active treatment was initiated in participants with a reduction in BMD from baseline of >7% at any anatomical site together with a T-score below −2.5. Participants receiving any rescue therapy were to continue receiving study medication.
| Study objectives
All primary and secondary efficacy hypotheses were tested at week 26. 10 Secondary objectives included assessment of the following at weeks 52 and 104: change from baseline in HbA1c, FPG, body weight, systolic blood pressure (SBP) and diastolic blood pressure (DBP); proportion of participants with HbA1c <7.0% (53 mmol/mol) and <6.5%
(48 mmol/mol); proportion of participants who received glycaemic rescue therapy; and change from baseline in BMD at the lumbar spine, femoral neck, total hip and distal forearm. The safety and tolerability of ertugliflozin were assessed through week 104.
| Efficacy assessments
Changes from baseline in HbA1c, FPG, body weight, SBP and DBP were evaluated at week 26 10 in Phase A and at weeks 52 and 104 in Phase B. The proportion of participants with HbA1c <7.0%
(53 mmol/mol) and <6.5% (48 mmol/mol), and the proportion receiving glycaemic rescue therapy, were also evaluated at week 26, 10 week 52 and week 104.
| Safety assessments
Safety assessments included adverse events (AEs), drug-related AEs, BMD at the lumbar spine (L1-L4), femoral neck, total hip and distal forearm was measured using dual-energy X-ray absorptiometry (DXA). All DXA scans were centrally analysed by an independent Central Evaluation Facility blinded to treatment allocation. 
| Statistical analyses
The Phase A and B descriptive efficacy and BMD analyses included all randomized and treated participants with baseline data and at least 1 post-randomization observation for the analysis endpoint. Change from baseline in efficacy endpoints at weeks 52 and 104 was assessed using a longitudinal data analysis (LDA) model for the ertugliflozin groups (with a constraint that baseline is the same, which is valid because of randomization) based on randomized and treated participants with at least 1 assessment at or after baseline. Efficacy endpoints were summarized using the excluding glycaemic rescue approach, i.e. efficacy data obtained after the initiation of glycaemic rescue therapy were censored (treated as missing). Raw mean changes from baseline are presented for the 3 treatment groups, and least squares (LS) mean changes from baseline (consistent with the analysis conducted at week 26 as previously reported 10 ) are presented in Supporting Information Table S1 for the ertugliflozin groups only.
Safety analyses included all randomized and treated participants.
With the exception of hypoglycaemia, safety analyses used the including glycaemic rescue approach. GMI by gender, UTI, symptomatic hypoglycaemia and hypovolemia AEs were prespecified for inferential testing without multiplicity control using the Miettinen and Nurminen method.
14 Data for BMD and bone turnover biomarkers are presented using an excluding bone rescue approach, i.e. data were censored at the point of a participant taking bone rescue therapy. The percentage changes from baseline in BMD endpoints at weeks 52 and 104 were assessed using an LDA model. An exploratory post hoc analysis also included change from baseline in body weight as a covariate to assess the impact of body weight loss on change in BMD from baseline to week 104. 15 Due to the addition of blinded glimepiride in Phase B for previously unrescued participants who were assigned to placebo in Phase A, and who met the fasting fingerstick glucose ≥6.1 mmol/L (≥110 mg/dL) criterion, no formal comparisons were made between the ertugliflozin and placebo/glimepiride groups at weeks 52 and 104 for efficacy or BMD analyses.
3 | RESULTS
| Participants
Overall, 621 participants were randomized, and 581 participants entered Phase B and received at least 1 dose of study medication in Phase B. Baseline characteristics were balanced across treatment groups (Supporting Information Table S2 ).
The proportion of participants who discontinued study medication in the Phase A and B treatment period was higher in the place- Table S3 ).
For all other reasons for discontinuation from study medication, the proportions were low and similar across treatment groups (Supporting Information Figure S3 ). Table S1 . (Table 1 ).
| Efficacy outcomes

| Prespecified AEs of special interest
The incidence of symptomatic hypoglycaemia was lower in the ertugliflozin 5 mg and 15 mg groups (5.8% and 5.9%, respectively) than in the placebo/glimepiride group (13.4%) (P = 0.009 for both ertugliflozin doses). The incidence of documented hypoglycaemia was 21.1%, 13.5% and 14.1% for placebo/glimepiride, ertugliflozin 5 mg and ertugliflozin 15 mg, respectively. There were no cases of severe hypoglycaemia. The incidence of GMIs was higher in the ertugliflozin groups compared with the placebo/glimepiride group for female participants (P = 0.017 for ertugliflozin 5 mg; P = 0.003 for ertugliflozin 15 mg). One female participant in the ertugliflozin 5 mg group discontinued study medication because of a GMI AE (vulvovaginal mycotic infection). None of the GMI events was serious, all were mild or moderate in intensity. The incidence of UTIs was not notably different (Table 1) .
| Adjudicated AEs
There were fewer confirmed fractures in both ertugliflozin groups than in the placebo/glimepiride group: ertugliflozin 5 mg, 3 fractures One participant in the ertugliflozin 15 mg group experienced a serious AE of diabetic ketoacidosis that met the charter case definition of 'certain to be ketoacidosis'; the participant had suspected type 1 diabetes (possible Latent Autoimmune Diabetes of Adulthood).
Three participants (1 in the ertugliflozin 5 mg group and 2 in the placebo/glimepiride group) had an AE of acute pancreatitis adjudicated as mild acute pancreatitis; none was considered to be caused by the study medication. One participant in the ertugliflozin 15 mg group had 1 renal event that was adjudicated as possibly related to study medication. One participant in the placebo/glimepiride group had an AE of liver injury that was adjudicated as possibly related to study medication.
Results of adjudication for cardiovascular events in this study will be analysed in a programme-wide manner across ertugliflozin clinical trials, and are not reported here.
| Additional safety topics
Three participants, 1 in the ertugliflozin 5 mg and 2 in the ertugliflozin 15 mg groups, underwent a non-traumatic lower limb amputation; all had either predisposing conditions or risk factors.
Initial mean reductions in eGFR at week 6 were followed by mean increases, returning to baseline levels at week 26. At week 104, the observed estimates of mean eGFR were slightly lower than baseline in the 3 treatment groups (Figure 3 ). Table S4 ).
| BMD and bone biomarkers
The changes in bone biomarkers were modest in the 3 treatment groups. CTX increased from study start in the 3 treatment groups, with the maximum mean percentage change from baseline observed Abbreviations: AE, adverse event; GMI, genital mycotic infection; UTI, urinary tract infection. a Assessed as related to the study drug by the investigator. b Two participants died more than 14 days after the last dose of study medication: 1 in the ertugliflozin 5 mg group (caused by acute heart failure) and another in the placebo/glimepiride group (caused by myocardial infarction). For the 4 deaths that occurred between the first dose of study medication and 14 days after the last dose of study medication, the causes were: plasma cell myeloma and unknown (ertugliflozin 15 mg), and hepatic cancer and cardiac death (placebo/glimepiride). None of the deaths was considered related to study medication by the investigators. For all other AEs, this table contains events that occurred between the first dose of treatment and 14 days after the last dose of treatment. c P = 0.009 for both ertugliflozin groups versus placebo/glimepiride. d P = 0.017 for ertugliflozin 5 mg versus placebo/glimepiride; P = 0.003 for ertugliflozin 15 mg versus placebo/glimepiride. at week 52. The mean percentage increases were higher in the ertugliflozin groups than in the placebo/glimepiride group throughout the study. P1NP also increased from baseline in the 3 treatment groups, and at week 104 the mean percentage increase in P1NP was higher with ertugliflozin 15 mg than with ertugliflozin 5 mg and placebo/glimepiride. PTH increased only slightly in the 3 treatment groups, and the mean percentage increase from baseline to week 104 was higher in the placebo/glimepiride than in the ertugliflozin groups (Supporting Information Table S5 ). The long-term effect of ertugliflozin reflects the fact that it acts independently of β-cell function and insulin secretion, 16 and hence it is not affected by the progressive β-cell failure observed in patients with T2DM. These data are consistent with glycaemic endpoints in other studies with ertugliflozin [8] [9] [10] [11] [12] [13] and other members of the SGLT2 inhibitor class. 17 Additionally, as previously established in other studies with ertugliflozin [8] [9] [10] [11] [12] [13] and other SGLT2 inhibitors, 17 ertugliflozin produces clinically relevant effects on important non-glycaemic endpoints such as body weight and SBP.
| Laboratory variables
During 2 years of treatment, ertugliflozin was well tolerated. The safety profile, including prespecified AEs of special interest, was consistent with the rest of the ertugliflozin development programme. [8] [9] [10] [11] [12] [13] Some AEs are of special interest because of findings in other SGLT2 inhibitors during the conduct of this study: lower limb amputations and ketoacidosis. In this study, 1 participant in the ertugliflozin 5 mg group and 2 in the ertugliflozin 15 mg group experienced a nontraumatic lower limb amputation and 1 participant in the ertugliflozin 15 mg group had a serious AE adjudicated as certain to be ketoacidosis.
At week 104, participants in the ertugliflozin group experienced minimal, non-clinically significant changes in BMD that were similar to those observed in the placebo/glimepiride group, except at the hip.
Body weight loss has been associated with increases in bone turnover and loss of BMD. 18 In this study, ertugliflozin was associated with clinically meaningful body weight loss, significantly greater than the placebo arm at week 26 and maintained throughout the study. In a post hoc analysis,~10% of the observed difference in the percentage reduction of BMD in the total hip between the ertugliflozin 15 mg group and the placebo group could be explained by changes in body weight. 15 However, this finding should be interpreted with caution given its exploratory nature. (−1.9, −0.6) for canagliflozin 100 mg and 300 mg versus placebo, respectively. 22 The studies cannot be directly compared because of on longitudinal data analysis model with fixed effects for treatment, time, prior antihyperglycaemic medication (metformin monotherapy or metformin and another antihyperglycaemic agent), baseline estimated glomerular filtration rate (continuous), menopausal status (men, premenopausal women, women who are perimenopausal or <3 years postmenopausal, women who are ≥3 years postmenopausal) and the interaction of time by treatment different designs, differences in participants' ages, and in the proportion of women in pre-, peri-and menopausal stages.
In conclusion, in patients with T2DM and inadequate glycaemic control on metformin monotherapy, adding treatment with ertugliflozin 15 mg and 5 mg provided clinically meaningful and durable improvements in glycaemic control, body weight and SBP over 104 weeks. Ertugliflozin was associated with minimal, non-clinically relevant changes in BMD. Ertugliflozin was generally well tolerated, but with a higher incidence of GMIs in female participants in the ertugliflozin groups relative to the placebo/glimepiride group, while the incidence of symptomatic hypoglycaemia was lower in both ertugliflozin groups than in the placebo/glimepiride group.
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